News By Tag Industry News News By Location Country(s) Industry News
| Coagulation Disorders Market to 2017The Global Coagulation Disorders Market is Forecast to Slow Down Due to a Series of Patent Expiries
By: Rajesh Gunnam representing a compound annual growth rate (CAGR) of 6.7% between 2002 and 2010. By 2017, the global coagulation disorders market is estimated to reach $8.3 billion, indicating a CAGR of 5.7% between 2010 and 2017. The major reason for the reduced growth rate is the expected decline in the annual cost of treating coagulation disorders after 2010. The global coagulation disorders market is expected to witness a series of patent expiries between 2010 and 2017, which includes most of the top selling blockbuster drugs in the hemophilia disease markets. The major drugs that are set to lose patent protection between 2010 and 2017 include NovoSeven (2010), ReFacto (2010), BeneFIX (2011) and Kogenate FS in the US (2014). While the current coagulation disorders pipeline does offer some promising products, the revenues generated from these products are not expected to completely offset the revenue lost due to the patent expiries. Therefore, the overall market growth of the global coagulation disorders market is expected to slow down in the future. For Sample Pages, please click or add the below link to your browser: http://www.gbiresearch.com/ The current coagulation disorders market scenario demands substantial output from the research and development (R&D) departments of pharmaceutical companies. With a series of patent expiries expected in the next seven years, disease indications such as hemophilia A and hemophilia B are set to lose billions of dollars of revenue from the market as a result. GBI Research, the leading business intelligence provider, has released its latest research, “Coagulation Disorders Market to 2017 - Hemophilia A, the Largest Segment, to Witness a Decline in Growth Rate due to Patent Expiries and Weak Pipeline”, provides in-depth analysis of unmet needs, drivers and barriers that impact the global coagulation disorders market. The report analyzes the markets for coagulation disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Market size, annual cost of therapy and treatment usage patterns are forecast until 2017 for the key geographies, as well as the leading therapeutic segments which includes hemophilia A, hemophilia B and von Willebrand Disease. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global coagulation disorders market. GBI Research’s analysis indicates that the global coagulation disorders market has been one of the fastest growing markets from 2002-2010. However, the market growth is expected to slow down in the future due to various restraints, such as the expiry of key drug patents across all disease segments, generic substitution, biosimilar penetration, and the decreasing annual cost of disease treatment in major markets such as the US, Japan and the top five countries in Europe. Nevertheless, the global coagulation disorders market is still forecast to grow at a moderate rate over the next seven years. For further details, please click or add the below link to your browser: http://www.gbiresearch.com/ Visit our report store: http://www.gbiresearch.com For more details contact: pressreleases@ North America: +1 646 395 5477 Europe: Asia Pacific: # # # GBI Research is a market-leading provider of business intelligence reports. GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders’ insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs. End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number